AIDS Treatment News logo      

September 18, 2009

Boosted protease inhibitor regimens with 3TC work despite M184V resistance

"People with HIV who have developed resistance to 3TC (lamivudine) can still achieve viral load suppression using boosted protease inhibitor regimens that include 3TC as part of the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) "backbone", researchers reported this week at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. ...

"Drug resistance generally increases the risk of treatment failure and disease progression, but the presence of the M184V mutation appears to decrease viral fitness by reducing its ability to replicate and increasing susceptibility to other NRTIs. This is demonstrated by the fact that viral load may increase by a small amount when people with this mutation stop taking 3TC, indicating that the drug had an antiviral effect despite resistance."

Read more in Aidsmap, September 18, 2009.

0 comments: